{ "@context": "https://orbyd.app/schemas/dossier.v1.json", "ticker": "TNGX", "name": "Tango Therapeutics, Inc.", "url": "https://orbyd.app/dossiers/TNGX/", "json_url": "https://orbyd.app/dossiers/TNGX.json", "status": "RECENTLY_EXITED", "current_conviction": "LOW", "graded_conviction": "MEDIUM", "archetype": { "code": "a7", "n": 7 }, "current_thesis": "Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17) into a falling price — a divergence that historically resolves toward price. Next hard data is ESMO in October.", "invalidation_trigger": "secondary condition: the 2026-08-04 Q2 update fails to put a dated Phase 3 initiation on the calendar, or the $100M Leerink ATM activates below the $30.00 offering price.", "catalyst_date": "2026-08-05", "outcome": "INVALIDATED", "outcome_date": "2026-07-02", "invalidation_fired": true, "themes": [ "oncology-immunology" ], "tags": [], "sources": [], "notes": [ "Vopimetostat = TNG462 renamed: an MTA-cooperative PRMT5 inhibitor aimed at MTAP-deleted cancers.", "Daraxonrasib and zoldonrasib are Revolution Medicines assets. Tango controls neither their labels, their supply, nor the front-line registrational design.", "Clinical-stage with no product revenue. Collaboration revenue fell to $0 in Q1 2026 after the Gilead agreement concluded, so the income statement carries little signal.", "Vendor quote pages still show a pre-offering count of 144,647,982 shares; the 424B5 filed 2026-06-10 states 162,329,210 outstanding after the June deal.", "Float estimates diverge sharply by provider, from 69.56M to roughly 135M. Shares outstanding is the stable denominator for any short-interest percentage.", "Matthew Gall succeeded Daniella Beckman as CFO effective 2026-04-15. A Form 144 is a notice of intent to sell, not evidence a sale occurred." ], "body_markdown": "## Current Thesis\n\nThe leg on offer is unchanged: a chemotherapy-free front-line regimen in MTAP-deleted pancreatic cancer, built on a partner backbone that is currently inside the FDA. What advanced since the last note is the tape and, more usefully, the filing record behind it.\n\nThe slide stopped. TNGX closed 2026-08-04 at $29.36, up $2.15 or 7.90%, reclaiming a 50-day average of $27.67 and a 20-day near $28.30. about three-quarters of an ordinary session. No Tango press release, SEC filing or rating action carries that date. Revolution Medicines rose 6.03% the same session to $193.46, within roughly 1% of its own 52-week high of $194.56. The move looks like partner beta rather than a bid for Tango.\n\nSecond, the balance sheet is better than the Q1 release implied. The offering 8-K filed 2026-06-10 puts net proceeds at approximately $566.5M and moves runway guidance from \"into 2028\" (Q1 release, 2026-05-13) to \"into 2030.\"\n\nThird, the equity-supply overhang is smaller than it has been read as. $62.1M of the $100M Leerink ATM had already been sold as of 2026-03-02. The 424B5 dated 2026-06-09 discloses that only $35.6M of capacity remained as of 2026-06-05, and that the company is barred from selling stock without J.P. Morgan and Leerink consent for 60 days from that prospectus date — a lock-up expiring around 2026-08-08.\n\nThat share count matters on its own. Vendor quote pages still carry 144,647,982 shares, the pre-offering figure from the 10-Q cover dated 2026-05-06. The 424B5 filed 2026-06-10 states 162,329,210 shares outstanding immediately after the offering (165,329,219 if the underwriters exercise their 3,000,009-share option in full; no 8-K disclosed an exercise before the window closed around 2026-07-09). Recomputed on the filed base, the 42,720,390-share short position at the 2026-07-15 settlement is 26.3% of shares outstanding — the stale denominator produces 29.5%. Every published \"percent of float\" figure inherits a float estimate ranging from 69.56M (stockanalysis.com) to 106.26M (finviz) to roughly 135M implied by MarketBeat.\n\nThe life-cycle label stays **SATURATED**. Dating it: Tango has published nothing since the 2026-06-22 board-appointment release (8-K filed 06-23), 44 days as of 2026-08-05; the last rating action was Canaccord's 2026-07-30 Buy reiteration at $46, with no firm moving since; turnover decayed from 21.8M shares on 2026-06-08 to a 20-day average of 2,453,791; and the 2026-08-04 advance arrived on below-average volume. A 7.9% session that trades fewer shares than a normal one is weak evidence of new participation.\n\n## Bull Case\n\n- **The 2026-06-08 dataset is still the strongest disclosed in the class.** At a 2026-05-28 cutoff, 12 response-evaluable PDAC patients on vopimetostat plus daraxonrasib produced 11 objective responses (9 confirmed), 90% six-month PFS, 100% disease control, median PFS not reached. The zoldonrasib arm: 27 evaluable, 52% ORR (14/27, 10 confirmed), 74% six-month PFS. No discontinuations for adverse events, no related Grade 4 or 5 events.\n- **The backbone is under active FDA review.** Revolution Medicines' daraxonrasib NDA in previously treated metastatic PDAC was accepted 2026-07-22 under the Commissioner's National Priority Voucher pilot, granted October 2025; the EMA opened an expedited phased assessment on 2026-07-07 under the Cancer Medicines Pathfinder project. An approved backbone converts the combination into a label-expansion path on a marketed drug.\n- **Financing is no longer the constraint the tape priced.** ~$566.5M net from the 2026-06-09 pricing of 18,166,667 shares plus 1,833,395 pre-funded warrants at $30.00, on top of $379.8M at 2026-03-31, funds operations into 2030 per the 2026-06-10 8-K. Remaining ATM capacity of $35.6M is immaterial against a share base of 162,329,210.\n- **The short base kept building through the drawdown.** 42,720,390 shares at 2026-07-15 versus 42,009,250 at 06-30 and 34,040,485 at 06-15. Published days-to-cover ranges from 10.71 (finviz) to 15.32 (MarketBeat) depending on the volume window.\n- **Insider selling is programmatic, not discretionary.** The 2026-08-03 Form 144 from Adam Crystal (President, R&D) notices 81,000 shares at $2,201,580 aggregate under a 10b5-1 plan adopted 2025-10-27, with the remark that the shares \"were and will be received upon the exercise of stock options over the next three months.\" Prior sales of 27,000 on 07/01 and 27,000 on 06/01 make 81,000 a three-month block at an unchanged monthly cadence.\n\n## Bear Case\n\n- **Nothing between now and 2026-10-23 resolves efficacy.** The company's own stated milestone is to \"finalize design of Phase 3 randomized-controlled trial of the combination approach in front-line pancreatic cancer in 2H 2026\" (2026-06-08 release, repeated verbatim in the 424B5 dated 2026-06-09) — design finalization, explicitly \"subject to feedback from regulatory authorities,\" not initiation. Fifty-eight days have passed since the data with no protocol, control arm or site disclosed.\n- **Small n, incomplete confirmation.** Eleven responses in twelve evaluable patients, of which nine were confirmed at the 2026-05-28 cutoff. A 92% ORR from a 12-patient single-arm cohort carries wide error.\n- **Fourteen consecutive closes beneath the June deal.** The last close at or above $30.00 was $30.25 on 2026-07-15; every session from 07-16 through 08-04 closed below it, and $29.36 is still 2.1% under the price institutions paid on 2026-06-09 and 14.6% below the 2026-06-17 high of $34.39.\n- **The comparator moved.** Daraxonrasib monotherapy delivered 13.2-month median OS, so a randomized combination study must beat an active control rather than chemotherapy — a harder and more expensive design.\n- **Two June sale notices remain unresolved on the public record.** Daniella Beckman's 2026-06-11 Form 144 for 1,791,726 shares ($51,523,582.08) and Nextech Crossover I SCSp's 2026-06-17 notice of 3,766,081 shares ($113,359,038) have not been closed out by any Form 4 or Schedule 13G/A. A Rule 144 notice is intent, not execution; a departed officer's Section 16 obligation can lapse, so silence resolves nothing either way.\n- **Sell-side panels have started to disagree.** stockanalysis.com shows 13 analysts, $44.33 average, 11 Buy / 1 Hold / 0 Sell; MarketBeat shows 16 analysts, $42.15 average, and 13 Buy / 2 Hold / 1 Sell over twelve months. The presence of a Sell in one panel is the first crack in what had been uniform positioning.\n\n## Setup & Price Structure\n\nThe 07-29 close of $25.85 is the lowest close since the June data and marks the base of the post-offering range. From there, price has put in a higher low and, on 08-04, its highest close since 07-15. Spot sits 6.1% above a 50-day average of $27.67 that is still rising as pre-June-8 prints roll off, and 66% above the 200-day of $17.66. The 52-week range is $6.21 to $34.39, the high dated 2026-06-17.\n\nCrowding observables, stated plainly: coverage is complete and one-directional, with no downgrade published since the 06-17 high; the short base is 42,720,390 shares, 26.3% of the post-offering share count; a company lock-up on further equity sales expires around 2026-08-08; and a Q2 print is imminent but undated by the company — vendor estimates split between 2026-08-04 (MarketBeat, Zacks) and 2026-08-05 (stockanalysis.com), against historical Q2 10-Q filings on 2025-08-05, 2024-08-07 and 2023-08-07. The 08-04 advance narrows the distance to the $30.00 deal price to 64 cents while volume runs below its own 20-day average.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-08-05 to ~2026-08-12 (est.)** — Tango Q2 2026 results and 10-Q. First disclosure of post-offering cash, whether the 3,000,009-share underwriter option was exercised, and any subsequent-events language on the ATM.\n- **2026-08-11** — publication of the 2026-07-31 short-interest settlement (FINRA schedule). Shows whether the short base kept building through the $25.85 low.\n- **2026-08-14** — Q2 2026 13F deadline and quarterly Schedule 13G/A date. 13Fs show which institutions still hold the $30.00 placement.\n- **~2026-08-22 to ~2026-09-22 (est.)** — possible FDA action on daraxonrasib under the CNPV pilot. No target action date was published in the 2026-07-22 acceptance release; the pilot is described as compressing review well below the standard ten months.\n- **2026-08-25** — publication of the 2026-08-14 short-interest settlement, the first read spanning the Q2 update.\n\n## Elapsed catalysts\n\n- **2026-08-05** — Revolution Medicines Q2 2026 results after the close, webcast 4:30 p.m. ET (announced 2026-07-29). The partner sets the clock on the CNPV review and states whether the vopimetostat combination sits inside RVMD's development plans. *(passed 4d ago)*\n- **~2026-08-08 (est.)** — expiry of the 60-day company lock-up dated from the 2026-06-09 prospectus supplement, after which the remaining $35.6M of ATM capacity becomes usable. *(passed 1d ago)*\n- **~2026-08-05 onward (est.)** *(passed 4d ago)*\n\n## What Would Change Our Mind\n\nThe structure that would have to fail first is the base built between 2026-07-29 and 2026-08-04: a higher low at $25.85 and a reclaim of the rising 50-day. A a daily close that breaches the risk threshold gives back the entire 08-04 advance and puts price under that average again, which would date the reclaim as a one-session partner-driven move with nothing behind it.\n\nOn the fundamental side, the specific thing that would break the frame is the Q2 update landing with the same sentence the company has used since 2026-06-08 — front-line Phase 3 design \"finalized in 2H 2026,\" subject to regulatory feedback — and no protocol identifier, no named control arm, no site activation. That would put the first hard efficacy or design datapoint at ESMO on 2026-10-23 and leave roughly eleven weeks with no resolvable question.\n\nThe third condition is supply. If the ~2026-08-08 lock-up expiry is followed by disclosed ATM sales beneath the $30.00 June offering price, that is a company willing to issue below the level institutions paid eight weeks earlier — with only $35.6M of capacity, the size would be immaterial but the signal would not be.\n\nWhat would work the other way: a dated Phase 3 initiation naming daraxonrasib as control, a Nextech 13G/A on 2026-08-14 showing the block cleared, or RVMD management on the 2026-08-05 call putting the combination inside its own registrational plans.\n\n## Correlation Notes\n\nTNGX trades as a derivative of Revolution Medicines. On 2026-08-04 RVMD gained 6.03% to $193.46 and TNGX gained 7.90% to $29.36, neither on an attributable dated release from either company; RVMD closed within about 1% of its 52-week high of $194.56 while TNGX sat 14.6% below its own. The dependency is structural, not sentiment: the vopimetostat combination is dosed on daraxonrasib and zoldonrasib, molecules Tango neither owns nor supplies, and the regulatory clock that matters most in the next 30 days is RVMD's CNPV review, not any Tango filing.\n\nSecondary correlations worth watching: clinical-stage oncology beta broadly, since a 5Y beta of 1.15 understates how the name has traded around binary readouts (21.8M shares on 2026-06-08 against a 2.45M 20-day average now); and the MTAP-directed cohort — navlimetostat (Bristol Myers Squibb), AMG 193 (Amgen), IDE397 (IDEAYA) — where a competing combination readout in MTAP-deleted PDAC would reprice the class rather than just this ticker.", "first_seen": "2026-04-19", "last_analyzed": "2026-08-05T05:51:43+00:00", "last_synthesized": "2026-08-05", "last_update_source": "watchlist_research", "license": "Content © orbyd. Cite the canonical URL." }